Stemline Therapeutics Inc (NASDAQ:STML) has been assigned an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $25.00.
Several research firms recently issued reports on STML. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a report on Monday, September 30th. Zacks Investment Research lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. Finally, BidaskClub lowered shares of Stemline Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 10th.
In other news, CEO Ivan Bergstein sold 35,010 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.73, for a total transaction of $515,697.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 13.10% of the stock is currently owned by corporate insiders.
STML stock traded up $0.01 during midday trading on Friday, hitting $9.03. The stock had a trading volume of 402,814 shares, compared to its average volume of 628,044. The firm has a market cap of $396.92 million, a P/E ratio of -3.02 and a beta of 1.41. The company has a current ratio of 4.71, a quick ratio of 4.57 and a debt-to-equity ratio of 0.01. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $18.22. The business has a fifty day moving average price of $10.45 and a two-hundred day moving average price of $13.35.
Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.05. The firm had revenue of $13.01 million during the quarter, compared to analyst estimates of $8.84 million. On average, equities analysts anticipate that Stemline Therapeutics will post -1.92 EPS for the current year.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Story: Convertible Shares
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.